Boost Run (BRUN) is rated Buy at around $15 after its share price fell 64%, supported by strong multi-year prepaid customer contracts that reduce capital risk. The company's business model focuses on securing contracts before hardware purchases, aligning growth with demand and improving cash returns from GPU systems. While reported gross margins appear high, true profitability depends on contract terms and execution, with risks including customer concentration and hardware obsolescence. The company aims to convert $1.9 billion in total contract value into $500–$600 million annual revenue by 2027, making it an attractive long-term investment despite current losses.
Boost Run's share price fell 64%, with a target price around $15, providing context for readers interested in this stock. For readers following the Technology sector, here is Pluang's market snapshot as of Sep 17, 2026 17:41 WIB: out of 150 priced US tech stocks, 133 rose and 14 fell today. Notable movers include CLSK at USD 13.16 (+2.89%, 79% buy orders, typical hold time 19 days), GLW at USD 148.31 (+2.83%, 71% sell orders, typical hold time 33 days), and TER at USD 350.55 (+2.76%, 93% sell orders, typical hold time 36 days).
Gainsight introduced its AI-native services business, Atlas, which manages over $75 million in annual recurring revenue (ARR) by handling long-tail customer renewals with AI agents and human managers. The company also announced a shift to value-based...
Owl Labs has introduced the Meeting Owl 5, a 4K UHD 360° teleconferencing camera designed for seamless hybrid meetings. It features a 20MP sensor, 360° fisheye lens, AI-powered audio with eight microphones, and an 18-foot voice pickup range. The devi...
Yields on stablecoins USDC and USDT derive from six sources including fund income, lending interest, trading fees, futures funding, platform rewards, and token incentives. Each source has different payers and risks, meaning a quoted annual yield may ...
XRP was trading at $1.30 on October 20 as Ripple Prime, Ripple's prime brokerage arm, joined a U.S. securities tokenization working group led by the Depository Trust & Clearing Corporation (DTCC). The group aims to develop a service to tokenize selec...
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
